Table 1.
Evidence table for therapeutic drugs of COVID-19.
| Category | Therapeutic Drugs | FIP Guidance6 | Chinese Guidance7 | WHO Guidance8 | CDC Guidance9 | CPA Guidance13 | Clinical Research14, 15, 16, 17, 18, 19, 20, 21 |
|---|---|---|---|---|---|---|---|
| Antiviral | Lopinavir-Ritonavir | ●a | ● | – | – | ● | ▲c△d |
| Arbidol | ● | ● | – | – | ● | ▲△ | |
| Interferon | ● | ● | – | – | ● | – | |
| Ribavirin | ● | ● | – | – | ● | – | |
| Remdesivir | −e | – | – | – | – | – | |
| Oseltamivir | – | – | – | – | – | – | |
| Favipiravir | – | – | – | – | ● | – | |
| Chloroquine phosphate | ● | ● | – | – | ● | – | |
| Hydroxychloroquine sulfate | – | – | – | – | – | ▲△ | |
| Immunomodulator | Corticosteroids | ◯b | ◯ | ◯ | ◯ | ◯ | △ |
| Tocilizumab | ◯ | ◯ | – | – | – | – | |
| Antimicrobials | Antibiotics | ◯ | ◯ | ◯ | – | ◯ | – |
a
●recommend.
b
◯recommend only if necessary.
c
▲significant effect.
d
△no significant difference compared with control group.
e
−not recommend or no current clinical research results.